Omfiloctocog alfa

DB19229InvestigationalProtein Based Therapies

Omfiloctocog alfa is under investigation in clinical trial NCT03947567 (Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia a Patients.).

Mechanism: Pharmacologically active on Coagulation factor VIII
Curator reviewed
Also known as: 1-740-BLOOD COAGULATION FACTOR VIII (RECOMBINANT HUMAN SCT800 HEAVY CHAIN) FUSION PROTEIN WITH HUMAN BLOOD COAGULATION FACTOR VIII B DOMAIN FRAGMENT (14-AMINO ACID LINKER) FUSION PROTEIN WITH BLOOD COAGULATION FACTOR VIII (RECOMBINANT HUMAN SCT800 LIGHT · HUMAN COAGULATION FACTOR VIII (FVIII, ANTIHEMOPHILIC FACTOR, AHF, PROCOAGULANT COMPONENT) WITH DELETED B-DOMAIN (746-1639)-SEQUENCE: SINGLE-CHAIN RECOMBINANT FVIII COMPOSED OF DOMAINS A1-A1-A2-A2 (1-740), THE B-DOMAIN N-AND C-TERMINAL FRAGMENTS (741-745)
Code names: SCT-800

Resolves to

Compound

UNII74D9ZOJ6IRCAS2249927-58-8

Targets

P00451F8

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Omfiloctocog alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account